The Technical Analyst
Opthea Limited [OPT]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Opthea Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.05% $3.56
/ 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 294.95 mill |
| EPS: | -2.41 |
| P/E: | -1.480 |
| Earnings Date: | Aug 29, 2024 |
| SharesOutstanding: | 82.85 mill |
| Avg Daily Volume: | 0.0262 mill |
| RATING 2024-04-15 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | n/a | ||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.480 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.480 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.957 (-73.12%) $-2.60 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.28 - 3.84 ( +/- 7.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2006-03-06 | Harrold Jason M | Sell | 7 000 | Employee Stock Option (right to buy) |
| 2006-03-06 | Harrold Jason M | Sell | 22 500 | Employee Stock Option (right to buy) |
| 2006-03-06 | Harrold Jason M | Sell | 15 000 | Common Stock, $.001 par value per share |
| 2006-03-06 | Harrold Jason M | Sell | 25 000 | Employee Stock Option (right to buy) |
| 2006-03-06 | Harrold Jason M | Sell | 125 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 21 transactions |
| Buy: 142 000 | Sell: 593 104 |
Forecast:
16:00 - $3.56
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.56
Forecast 2: 16:00 - $3.56
Forecast 3: 16:00 - $3.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.56 (-7.05% ) |
| Volume | 0.0042 mill |
| Avg. Vol. | 0.0262 mill |
| % of Avg. Vol | 16.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OPT
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Last 10 Buy Signals
Latest Press Releases
2024-04-08 18:42:00 - Press Release
Opthea Appoints John Han, Pharmd, As Vp Medical Affairs
Melbourne, australia and princeton, n.j., april 08, 2024 (globe newswire) -- opthea limited (asx/nasdaq: opt “opthea”, the “company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet amd), today announced the appointment of john han, pharmd, to the role of vice president, medical affairs, effective april 9, 2024.
2024-04-04 18:34:00 - Press Release
Opthea To Participate In The 23ʳᵈ Annual Needham Virtual Healthcare Conference
Melbourne, australia and princeton, n.j., april 04, 2024 (globe newswire) -- opthea limited (asx/nasdaq: opt “opthea”, the “company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet amd), today announced that management will present at the 23rd annual needham virtual healthcare conference and participate in one-on-one investor meetings on april 11, 2024.
2024-04-03 17:39:00 - Press Release
Opthea Appoints Sujal Shah To The Board Of Directors
Former cymabay therapeutics ceo brings extensive leadership experience to his role as a non-executive director and audit and risk committee chair former cymabay therapeutics ceo brings extensive leadership experience to his role as a non-executive director and audit and risk committee chair
2024-03-19 06:00:00 - Press Release
Opthea To Host Key Opinion Leader Event On Sozinibercept (opt-302) In Wet Age-related Macular Degeneration On April 3, 2024
Melbourne, australia and princeton, n.j., march 19, 2024 (globe newswire) -- opthea limited (asx:opt; nasdaq:opt; “opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced it will host a virtual key opinion leader (kol) event on wednesday, april 3, 2024, from 10:00 to 11:30 am et, featuring presentations from global retina experts:
2024-03-05 17:08:00 - Press Release
Opthea To Participate In The Leerink Partners Global Biopharma Conference
Melbourne, australia, march 05, 2024 (globe newswire) -- opthea limited (asx:opt; nasdaq:opt; “opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the leerink partners global biopharma conference being held in miami, florida on march 11-13, 2024.
Latest News
2024-04-03 09:53:16 - InvestorPlace
7 Growth Stocks to Buy to Outperform the Nasdaq Index
As investors, we all aim to outperform the market. But beating the S&P 500 is a difficult task for most of us.
2023-12-01 05:30:00 - GlobeNewsWire
Opthea to Present at the FLORetina 2023 Congress
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.
2023-11-09 05:30:00 - GlobeNewsWire
Opthea to Present at the Jefferies 2023 London Healthcare Conference
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023.
2023-10-30 05:30:00 - GlobeNewsWire
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder & Chief Innovation Officer, will present at Eyecelerator which is part of AAO 2023 being held in San Francisco, CA on November 3rd to 6th, 2023.
2023-09-07 05:30:00 - GlobeNewsWire
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company's Chief Financial Officer will present at H.C. Wainwright's 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023.
2023-07-24 06:00:00 - GlobeNewsWire
Opthea to Present at the 2023 Ophthalmology Innovation Summit
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at the 2023 Opthalmology Innovation Summit being held in Seattle, WA on July 27th, 2023.
2023-05-25 06:00:00 - GlobeNewsWire
Opthea to Present at the Jefferies 2023 Healthcare Conference
MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York City on June 7-9 2023.
2023-05-08 05:30:00 - GlobeNewsWire
Opthea To Present at the JMP Securities Life Sciences Conference
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company's Chief Financial Officer will present at the JMP Securities Life Sciences Conference being held in New York City on May 15-16 2023.
2023-02-06 06:00:00 - GlobeNewsWire
Opthea To Present at SVB Leerink Global Biopharma Conference
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at SVB Leerink's Global Biopharma Conference being held virtually on February 14-16, 2023.
2023-01-30 06:00:00 - GlobeNewsWire
Opthea To Present at Sequire Biotechnology Conference
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.